Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: Case report and review

Clinical Infectious Diseases

Volumn 28, Issue 5, 1999, Pages 1134-1138

  Segal Maurer, Sorana ^a   Mariano, Noriel ^b   Qavi, Abdul ^b   Urban, Carl ^b   Rahal Jr , James J ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFTAZIDIME; IMIPENEM; MEROPENEM; POLYMYXIN B;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BRAIN VENTRICLE PERITONEUM SHUNT; BRAIN VENTRICULITIS; CASE REPORT; CEREBROSPINAL FLUID CULTURE; FEMALE; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KLEBSIELLA PNEUMONIAE; MENINGIOMA; MULTIDRUG RESISTANCE; NEUROSURGERY; PRIORITY JOURNAL;

EID: 0032940951     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514754     Document Type: Article

References (36)

1. 1. Quinn JP. Clinical significance of extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis 1994; 13(suppl 1):39-42.
2. 2. Segal-Maurer S, Urban C, Rahal JJ. Current perspectives on multidrug-resistant bacteria: epidemiology and control. Infect Dis Clin North Am 1996; 10:939-57.
3. 3. Livermore DM, Yuan M. Antibiotic resistance and production of extended-spectrum β-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother 1996; 38:409-24.
4. 4. Decré D, Gachot B, Lucet JC, Arlet G, Bergogne-Bérézin E, Régnier B. Clinical and bacteriologic epidemiology of extended-spectrum β-lactamase-producing strains of Klebsiella pneumoniae in a medical intensive care unit. Clin Infect Dis 1998; 27:834-44.
5. 5. Peña C, Pujol M, Ardanuy C, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 1998; 42:53-8.
6. 6. Livermore DM. β-lactamase-mediated resistance and opportunities for its control. J Antimicrob Chemother 1998; 41:25-41.
7. 7. Shannon K, Stapleton P, Xiang X, et al. Extended-spectrum β-lactamase-producing Klebsiella pneumoniae strains causing nosocomial outbreaks of infection in the United Kingdom. J Clin Microbiol 1998; 36:3105-10.
8. 8. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 4th ed. Approved standard M7-A4. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards, 1997.
9. 9. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents. Tentative guideline M26-T. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards, 1992.
10. 10. National Committee for Clinical Laboratory Standards. Methodology from serum bactericidal test. Tentative guideline M21-T. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards, 1992.
11. 11. Maslow JN, Slutsky AM, Arbeit RD. Application of pulsed-field gel electrophoresis to molecular epidemiology. In: Persing DH, Smith TF, Tenover KC, White TJ, eds. Diagnostic molecular microbiology: principles and applications. Washington, DC: American Society for Microbiology, 1993:563-72.
12. 12. King TC, Schlessinger D, Krogstad DJ. The assessment of drug combinations. Rev Infect Dis 1981; 3:627-33.
13. 13. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33:2233-9.
14. 14. Hayes ER, Yow D. Meningitis due to Pseudomonas aeruginosa treated with polymyxin B. Am J Med Sci 1950; 220:633-7.
15. 15. Biehl JP, Hamburger M. Polymyxin B therapy of meningitis following procedures on central nervous system. Arch Intern Med 1954; 93: 367-78.
16. 16. Furey W, Ciric I, Parker RH. Monitoring of intrathecal polymyxin B dosage during treatment of pseudomonas meningitis. Illinois Medical Journal 1971; 139:506-10.
17. 17. Geelhoed GW, Ketcham AS. Pseudomonas meningitis complicating radical resection for recurrent cancer of the paranasal sinuses: report of two patients successfully treated with intrathecal polymyxin. J Surg Oncol 1973; 5:365-74.
18. 18. Rahal JJ. Diagnosis and management of meningitis due to gram-negative bacilli in adults. Curr Clin Top Infect Dis 1980; 1:68-84.
19. 19. Rahal JJ, Simberkoff MS. Host defense and antimicrobial therapy in adult gram-negative bacillary meningitis. Ann Intern Med 1982; 96:468-74.
20. 20. Swartz MN. Intraventricular use of aminoglycosides in the treatment of gram-negative bacillary meningitis: conflicting views. J Infect Dis 1981; 143:293-6.
21. 21. Wise BL, Mathis JL, Jawetz E. Infections of the central nervous system due to Pseudomonas aeruginosa. J Neurosurg 1969; 31:432-4.
22. 22. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC β-lactamase, and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997; 41: 563-9.
23. 23. Ahmad M, Urban C, Mariano N, et al. Molecular epidemiology of imipenem resistant Klebsiella pneumoniae [abstract]. Presented at the 34th Annual Meeting of the Infectious Diseases Society of America, New Orleans, 1996.
24. 24. Nau R, Lassek C, Kinzig-Schippers M, Thiel A, Prange HW, Sorgel F. Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy. Antimicrob Agents Chemother 1998; 42:2012-6.
25. 25. Rahal JJ, Hyams PJ, Simberkoff MS, Rubinstein E. Combined intrathecal and intramuscular gentamicin for gram-negative meningitis. N Engl J Med 1974; 290:1394-8.
26. 26. McGill RJ, Mendel D. Polymyxin B: an intrathecal reaction. Lancet 1953; 2:1293-4.
27. 27. Trapnell DH. Pseudomonas pyocyanea meningitis successfully treated with polymyxin B. Lancet 1954; 266:759-61.
28. 28. Tomlin CE. Pseudomonas meningitis: report of a case with recovery after polymyxin B therapy. Arch Intern Med 1951; 87:863-7.
29. 29. Teng P, Johnson BA. Experimental intracistemal injection of polymyxin B: its role in the treatment of septic meningitis. Neurology 1953; 3:831-43.
30. 30. Nunn SL, Wellman WE. Pseudomonas meningitis: report of a case. Med Clin North Am 1960; 44:1075-8.
31. 31. Everett ED, Strausbaugh LJ. Antimicrobial agents and the central nervous system. Neurosurg 1980; 6:691-714.
32. 32. Tauber MG, Shibl AM, Hackbarth C, Larrick JW, Sande MA. Antibiotic therapy, endotoxin concentration in CSF, and brain edema in experimental meningitis in rabbits. J Infect Dis 1987; 156:456-62.
33. 33. Clark KL, Jervey LP, Freiman DG, Hamburger M. The toxicity of intracisternally injected polymyxin B in the rhesus monkey. Antibiotics Annual 1955-1956, 1956:428-31.
34. 34. Simon C, Lang F, Holzman RS. Successful treatment of Acinetobacter calroaceticus ventriculitis and development of subsequent chemical meningitis following intraventricular polymyxin B [abstract no 207]. Presented at the 32nd Annual Meeting of the Infectious Diseases Society of America, Orlando, 1994.
35. 35. Quintiliani R, Lentnek A. Polymyxin B in the treatment of Klebsiella pneumonias meningoventriculitis. Am J Dis Child 1971; 121: 239-42.
36. 36. Chin NX, Scully B, Della-Latta P. In vitro synergy of polymyxin B with imipenem and other antimicrobial agents against Acinetobacter, Klebsiella, and Pseudomonas species [abstract no E-56]. In: Program and abstracts of the 38th International Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 1998:184.